Teva's olanzapine LAI shows no PDSS events in long-term trial data
PositiveFinancial Markets

Teva's recent long-term trial data for olanzapine long-acting injection (LAI) has shown no occurrences of PDSS events, which is a significant finding for patients and healthcare providers. This is important because it suggests that the medication may be safer than previously thought, potentially improving treatment options for those with schizophrenia and bipolar disorder. The absence of PDSS events could lead to increased confidence in prescribing this medication, ultimately benefiting patient care.
— Curated by the World Pulse Now AI Editorial System